Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2023

Are Outcome Trials Necessary for Renal Denervation Therapies?

Presenter: Ajay Kirtane

October 24, 2023

Presentation TCT 2023

What Will the Next Trial Designs Look Like for Renal Denervation?

Presenter: Eric Secemsky

October 24, 2023

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

Presentation TCT 2021

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Presenter: Ajay Kirtane

November 04, 2021

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Shelley Wood

October 09, 2020

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

Presentation TCT 2018

RADIOSOUND-HTN: A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension

Presenter: Felix Mahfoud, Patrick W. Serruys, Philipp Lurz

September 25, 2018

Presentation TCT 2018

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Presenter: John A. Bittl, Bernard J. Gersh, Michael A. Weber

September 24, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

Presentation TCT 2017

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Presenter: Robert A. Byrne, Gregg W. Stone, Aaron V. Kaplan

October 30, 2017

Presentation TCT 2017

Does Left Ventricular Hypertrophy Compromise Coronary Flow Reserve and Affect Intervention Choices?

Presenter: Mark C. Bates, Bernard J. Gersh, Justin E. Davies

October 30, 2017

Advertisement

Are Outcome Trials Necessary for Renal Denervation Therapies?

What Will the Next Trial Designs Look Like for Renal Denervation?

New Faces, New Formats, New Tech: What to Expect From TCT 2022

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

RADIOSOUND-HTN: A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Does Left Ventricular Hypertrophy Compromise Coronary Flow Reserve and Affect Intervention Choices?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content